EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Randomisierte kontrollierte StudieVergleichsstudie

A Phase 1 Bioequivalence Study to Assess the Pharmacokinetics, Safety and Tolerability of Guselkumab After a Single‐Dose Administration via Two Subcutaneous Injection Devices in Healthy Volunteers

Angela Jeong, Kathleen Weisel, Dessislava Dimitrova, Brianna Donnelly, Daniel Wang, An Vermeulen, Zhenhua Xu

Clinical Pharmacology in Drug Development · 2026

DOI: 10.1002/cpdd.70007 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Clinical Pharmacology in Drug Development, 2026. Verfasst von Angela Jeong und 6 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacology and Pharmacometrics, Johnson & Johnson, Spring House, PA, USA. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized. Die Arbeit nennt 21 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Guselkumab is approved for the treatment of psoriasis, psoriatic arthritis, as well as ulcerative colitis and Crohn's disease. Two delivery devices for subcutaneous (SC) injection previously had been approved for the administration of 100 mg guselkumab. This study was designed to demonstrate the bioequivalence and tolerability of guselkumab following a single‐dose SC administration of 100 mg guselkumab using a 1 mL prefilled syringe (PFS) assembled with an Ypsomate autoinjector (i.e., 1 mL PFS‐Y, Test device) as compared to the approved 1 mL PFS assembled with the UltraSafe Plus needle safety guard (i.e., 1 mL PFS‐U, Reference device). Mean serum guselkumab concentration–time profiles were nearly superimposable for both devices following a single SC injection. The geometric mean ratios and the corresponding 90% confidence interval [CI] for C max and AUC inf were 102.28% (94.85%–110.30%) and 102.10% (95.19%–109.51%), respectively. There were no significant differences in the incidence of treatment‐emergent adverse events between the two treatment groups, and the incidence of treatment‐emergent anti‐drug antibodies was low and comparable between the two groups. Overall, these results suggest that the pharmacokinetics, safety/tolerability, and immunogenicity of guselkumab are comparable when administered via the 1 mL PFS‐Y and 1 mL PFS‐U.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedHumansTherapeutic EquivalencyInjections, SubcutaneousMaleAdultFemaleHealthy VolunteersYoung AdultArea Under CurveMiddle AgedCross-Over StudiesSyringes

Stichwörter der Autor:innen

autoinjectorbioequivalencedrug–device combinationguselkumabinterleukin 23monoclonal antibodypharmacokineticsprefilled syringe

Substanzen

guselkumabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Clinical Pharmacology and Pharmacometrics, Johnson & Johnson, Spring House, PA, USA.
  • Immunology Clinical Development, Johnson & Johnson, Spring House, PA, USA.
  • Preclinical Sciences & Translational Safety, Johnson & Johnson, Spring House, PA, USA.
  • Statistics & Decision Science, Johnson & Johnson, Titusville, NJ, USA.
  • Clinical Pharmacology and Pharmacometrics, Johnson & Johnson, Beerse, Belgium.

Zitieren

APA

Jeong, A., Weisel, K., Dimitrova, D., Donnelly, B., Wang, D., Vermeulen, A., & Xu, Z. (2026). A Phase 1 Bioequivalence Study to Assess the Pharmacokinetics, Safety and Tolerability of Guselkumab After a Single‐Dose Administration via Two Subcutaneous Injection Devices in Healthy Volunteers. Clinical Pharmacology in Drug Development. https://doi.org/10.1002/cpdd.70007

Vancouver

Jeong A, Weisel K, Dimitrova D, Donnelly B, Wang D, Vermeulen A, et al. A Phase 1 Bioequivalence Study to Assess the Pharmacokinetics, Safety and Tolerability of Guselkumab After a Single‐Dose Administration via Two Subcutaneous Injection Devices in Healthy Volunteers. Clinical Pharmacology in Drug Development. 2026. doi:10.1002/cpdd.70007

BibTeX
@article{Jeong2026,
  author = {Jeong, Angela and Weisel, Kathleen and Dimitrova, Dessislava and Donnelly, Brianna and Wang, Daniel and Vermeulen, An and Xu, Zhenhua},
  title = {A Phase 1 Bioequivalence Study to Assess the Pharmacokinetics, Safety and Tolerability of Guselkumab After a Single‐Dose Administration via Two Subcutaneous Injection Devices in Healthy Volunteers},
  journal = {Clinical Pharmacology in Drug Development},
  year = {2026},
  doi = {10.1002/cpdd.70007}
}
Kostenlos starten →